Engineered T Cells Market provides a quantitative analysis to enable the stakeholders to capitalize on prevailing market opportunities

Global engineered T cells market is growing at a CAGR of 46.5%, anticipated to reach $2,124 million by 2023, from 2017 to 2023.

Geographically, North America dominated the engineered T cells market, accounting for approximately half of the overall market in 2016. This can be attributed to various factors such as presence of leading biotech companies and modern research facilities in the region. Furthermore, Asia-Pacific is projected to register the highest growth due to surge in number of biopharmaceutical companies and increase in acceptance of modern cancer treatments.

Engineered T cells are also known as specifically modified T cells, which are designed for the treatment of autoimmune diseases, primary immune deficiencies, and cancer. Upon delivery, engineered T cells enable reduction of toxicities and inhibit antigen escape (inability of immune system to respond to an infectious agent). The engineered T cells assist immune system to overcome the immunosuppressive tumor microenvironments and target cancer cells for effective treatment.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/4538?utm_source=sy-Openpr

The major players profiled operating in the global engineered T cells market are
• Autolus Limited
• Bellicum PharmaceuticalsInc.
• Cells Medica
• Elli Lilly and Company
• Gilead SciencesInc.
• Juno Therapeutics
• Novartis AG
• Oxford Biomedica
• Pfizer Inc.
• Precision Bioscience

Increase in global prevalence of cancer and surge in demand for innovative biopharmaceutical therapies is projected to drive the growth of the engineered T cells market. In addition, advantages offered by engineered T cells therapies such as targeted action and less side effects are expected to boost the demand for engineered T cells in future.

Chimeric antigen receptor (CAR) modified T cells segment is projected to dominate the market during the analysis period, due to surge in utilization of chimeric antigen receptor T cells in research facilities.

By application, lung cancer garnered the highest market share in 2016, and expected to dominate during the analysis period, owing to increase in incidence of lung cancer and high utilization of engineered T cells for the treatment of lung cancer.

Hospitals have the extensive use of engineered T cells, hence, it held the highest market value in 2016, and is expected to lead the market during the analysis period.

Buy Now (Data Pack Available with Discounted Price): @ https://www.alliedmarketresearch.com/checkout/856692?utm_source=sy-Openpr

Key Findings of the Engineered T-cells Market:
• Chimeric antigen receptor modified T Cells segment accounted for more than half of the global market share in 2016.
• T cells receptor (TCR) segment is expected to grow at a highest CAGR.
• Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by Europe.
• China and India are the major market shareholders in Asia-Pacific.

Access Full Summery @ https://www.alliedmarketresearch.com/engineered-T-cells-market?utm_source=sy-Openpr

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.